Daratumumab, an anti-CD38 monoclonal antibody targeting plasma cells, has emerged as a potential therapy for recurrent focal segmental glomerulosclerosis (FSGS) after kidney transplantation; however, data on subcutaneous administration and its use in de novo disease are limited. We report 3 kidney transplant recipients with recurrent (n = 1) and de novo (n = 2) FSGS who were plasma exchange-dependent and/or rituximab-resistant and treated with subcutaneous daratumumab. All patients achieved remission, with sustained reductions in albuminuria and stable graft function at follow-up. Treatment was well tolerated, with no injection-related reactions; 1 patient developed transient neutropenia and oral ulcers. Subcutaneous daratumumab may represent a feasible and effective option for recurrent and de novo FSGS after kidney transplantation, including refractory cases, in conjunction with anti-CD20 therapy. Prospective studies are needed to define its role as monotherapy and the durability of response.

A 34-year-old male with poorly controlled diabetes mellitus with a painful necrotic ulcer over the lateral tongue, an uncommon site for mucormycosis. Histopathology confirmed broad aseptate right-angle bronching hyphae consistent with primary lingual mucormyosis. Early surgical debridement, glycemic optimization, and liposomal amphotericin B resulted in favourable clinical recovery, highlighting the importance of prompt recognition of atypical oral lesions in immunocompromised patients.

Hyaluronic acid (HA)-based microneedles have emerged as highly promising minimally invasive platforms for transdermal and transmucosal drug delivery, overcoming the limitations of conventional oral, topical, and injectable therapies. Owing to its excellent biocompatibility, biodegradability, hydrophilicity, non-immunogenicity, and intrinsic bioactivity, HA functions not only as a structural biomaterial but also as a therapeutic component that enhances tissue hydration, wound healing, immune modulation, and drug bioavailability. This review provides a comprehensive overview of the major fabrication strategies used for HA-based microneedles, including micro-molding, photolithography, centrifugal lithography, droplet-born air blowing, and additive manufacturing approaches. The effects of these techniques on microneedle geometry, mechanical strength, drug-loading capacity, dissolution behavior, and controlled-release performance are critically discussed. Recent biomedical applications of HA-based microneedles are systematically summarized, including transdermal drug delivery, vaccination and immunotherapy, diabetic and burn wound healing, oral ulcer treatment, allergy desensitization, alopecia areata therapy, ophthalmic delivery, and photodynamic therapy for oral leukoplakia. Particular emphasis is placed on multifunctional systems integrating nanoparticles, liposomes, antimicrobial agents, growth factors, antioxidants, and immunomodulatory compounds to achieve synergistic therapeutic effects. The review also highlights the mechanisms through which HA-mediated swelling, hydration, and biodegradation facilitate efficient and sustained drug release after microneedle insertion into biological tissues. Despite significant progress, challenges related to large-scale manufacturing, long-term stability, sterilization, dose reproducibility, and regulatory approval remain barriers to clinical translation. Overall, HA-based microneedles represent versatile next-generation platforms with strong potential for safe, effective, and patient-compliant biomedical applications.

An 11-year-old domestic shorthair cat presented for evaluation of severe oral haemorrhage. The patient had documented flea infestation and a history of marked pruritus preceding the onset of bleeding. Clinical examination identified a solitary lesion on the rostral hard palate as the only apparent source of haemorrhage. Histopathological analysis of the lesion revealed features consistent with trauma-induced ulceration, including fibrino-suppurative inflammation and granulation tissue proliferation. Based on the lesion's location, clinical history and histopathological findings, a diagnosis of Menrath ulcer was established, presumed to be secondary to excessive grooming behaviour associated with pruritic skin disease.

Systemic lupus erythematosus (SLE) can affect multiple organs, including the lungs, with a reported frequency ranging from 20% to 90%. Organizing pneumonia (OP) is a rare and uncommon presentation that may be life-threatening. A 42-year-old male presented with respiratory symptoms, fever, a history of recurrent pneumonia, and the development of oral ulcers. Antinuclear antibodies were positive with an AC-01 pattern, and he scored 10 points according to the 2022 European Alliance of Associations for Rheumatology (EULAR) classification criteria, establishing the diagnosis of SLE. Corticosteroid therapy was initiated with clinical resolution. We conducted a search in the PubMed database for cases of systemic lupus erythematosus that initially presented with organizing pneumonia. The search terms used were "organization" or "organized", or "organizing", and "pneumonia" and "lupus" or "systemic lupus erythematosus". It should be noted that no time filter was applied, and reports of cases of individuals under 18 years of age were excluded. OP was diagnosed as the initial manifestation of SLE, representing a diagnostic challenge in the absence of other guiding symptoms. We identified 19 case reports describing OP as the initial presentation of SLE. This case illustrates the diagnostic complexity and variability of SLE, and how OP, in the appropriate clinical context, should raise suspicion of SLE onset.